Acticor Biotech Confirms Simbec-Orion to Make Its First in Patient Study in Acute Ischemic Stroke

PARIS–(BUSINESS WIRE)–Acticor Biotech, a clinical stage biotechnology company involved in the
acute phase of thrombotic diseases, including stroke and pulmonary
embolism, as part of the development of its first drug candidate ACT017
who has just successfully completed a phase 1 study in the healthy
volunteer, confided to Simbec-Orion carrying out his first in patient
study, in acute ischemic stroke.

This phase 2 study, which will include a first group of 100 patients in
8 European countries, must be used to confirm the patient’s safety of
use while trying to provide evidence of vascular and neurological
efficacy.

This randomized study will be conducted in expert centers that can
accommodate this type of patient 24 hours a day, 7 days a week, giving
them the best standard of care, namely intravenous thrombolysis and
thrombectomy.

It is precisely this standard of care that will be used as a comparison
with ACT017, which will be injected as a 6-hour infusion in addition to
the standard of care.

The study will start in the autumn and the submission of the protocol to
the competent authorities of the countries concerned will be made
starting in June.

Dr. Gilles Avenard, CEO of Acticor Biotech commented on this decision: “This
study is key for us because it initiates all the clinical development of
our drug candidate in a severe and frequent indication in dire need of
new treatments. It was essential that it be conducted with the best
experts and European centers we trust. We selected Simbec-Orion
following a very wide consultation based on their international
experience in this indication. Our goal is to confirm the interest of
inhibition of platelet glycoprotein GPVI in patients in acute ischemic
phase. “

Fabrice Chartier, Group Chief Operating Officer of Simbec-Orion,
commented: “We are very honored to have been chosen by Acticor
Biotech for this essential study. We are very confident in the
professionalism of the R & D team of this company and also in the value
of this very innovative project. This is an important challenge too, as
such studies are highly qualified and require constant attention. It is
in the spirit of Simbec-Orion to seek to meet such challenges and be a
partner of choice for innovation companies. “

About Simbec -Orion – http://www.simbecorioncro.com/

About ACT017, the Therapeutic Candidate – https://acticor-biotech.com/technology/

About Acticor Biotech – https://acticor-biotech.com/

Contacts

Acticor Biotech:
Gilles Avenard
Chief Executive Officer
gilles.avenard@acticor-biotech.com
or
Media
– NewCap:

Annie-Florence Loyer
+33(0) 1 44 71 00 12 /
+33(0) 6 88 20 35 59
afloyer@newcap.fr